2023
DOI: 10.1016/j.jconrel.2023.04.039
|View full text |Cite
|
Sign up to set email alerts
|

Emerging nanoparticle platforms to improve the administration of glucocorticoids

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 152 publications
0
2
0
Order By: Relevance
“…Indeed physical encapsulation leads to drug loadings around 10-20 % at maximum [33], hydrophilic polymer prodrugs to drug loadings from 1% to 33 % at best for [18][19][20] and up to 50% for amphiphilic polymer conjugates of glucocortocoids [21,22]. Our LDC NP are definitely in the upper range of DXM loading [34].…”
Section: Ldc Encapsulation Efficiency and Ldc And Drug Loadingmentioning
confidence: 77%
“…Indeed physical encapsulation leads to drug loadings around 10-20 % at maximum [33], hydrophilic polymer prodrugs to drug loadings from 1% to 33 % at best for [18][19][20] and up to 50% for amphiphilic polymer conjugates of glucocortocoids [21,22]. Our LDC NP are definitely in the upper range of DXM loading [34].…”
Section: Ldc Encapsulation Efficiency and Ldc And Drug Loadingmentioning
confidence: 77%
“…However, the side effects of long-term use seriously affect its efficacy. Recent studies have shown that prodrug administration in the form of NPs has gradually become a research direction worth exploring [ 123 ]. In a study, cancer cell membrane-coated NPs were used to alleviate autoimmune diseases by harnessing the immunosuppressive effects of tumor cells.…”
Section: Application Of Nanomaterials In Gn Treatmentmentioning
confidence: 99%
“…Therefore, novel drug delivery systems such as liposomes [23] , [24] , [25] , [26] , micelles [27] , [28] , [29] , [30] , inorganic carriers [31] , [32] , [33] and prodrugs [34] , [35] , [36] , [37] have attracted the attention of researchers for enhancing drug targeting and reducing side effects in recent decades. However, there are limited marketed products based on liposomes and polymeric micelles, and only 13 products such as amphotericin B, doxorubicin hydrochloride, irinotecan hydrochloride, vincristine sulfate, dibucaine, cytarabine and daunorubicin compound liposomes are currently approved by FDA, while micelle-based products are even less available.…”
Section: Introductionmentioning
confidence: 99%